![](http://dmle128v1x6xv.cloudfront.net/media/7091/explore_stada_image_9-16_01.jpg)
For responsible production and consumption, STADA contributes to SDG 12 by finding innovative ways to be more sustainable through the entire lifecycle of its products.
Select your country
Websites worldwide
Select a country to go to the website of the respective STADA sales company.
Australia (1)
Austria (1)
Belarus (1)
Belgium (1)
Bosnia-Herzegovina (1)
Bulgaria (1)
China (1)
Croatia (1)
Czech Republic (2)
Denmark (1)
France (1)
Hungary (1)
Ireland (1)
Italy (1)
Montenegro (1)
Netherlands (2)
Poland (1)
Portugal (1)
Romania (1)
Saudi Arabia (1)
Serbia (1)
Slovakia (1)
Slovenia (1)
Spain (1)
Switzerland (1)
The Phillippines (1)
United Arab Emirates (1)
United Kingdom (3)
Vietnam (2)
We are looking for qualified employees who drive our company forward with their specialist knowledge and commitment. We offer appealing conditions with diverse and exciting tasks as well as good career prospects and a motivating working environment.Ā
With its as per today seven marketed biosimilars and more in the pipeline for the coming years, STADA is one of the leading biosimilar suppliers in Germany.6 Comprehensive expertise in manufacturing, sales and marketing makes STADA a strong partner for patients, doctors, wholesalers, hospitals, pharmacists and health insurance companies in Germany. The production of all STADA biosimilars in Germany or other European countries also contributes to the reliable supply security of STADA's biosimilars. STADA means "Biosimilar Expertise from Germany!" We are proud of this and it makes us strong!
Many thanks to the whole team, local and global, who made the seemingly impossible possible with incredible commitment and motivation. Here in the photo (but by no means all!): Caro Porth, Dr. Andreas Schliephake, Daniel Hohn, Vladislav Holata and Bjƶrn-Axel Berg
Note: UzpruvoĀ® is currently not authorised for the indication ulcerative colitis (as the original manufacturer still has exclusivity for this indication).
1 DURCHFĆHRUNGSBESCHLUSS DER KOMMISSION vom 5.1.2024 Ć¼ber die Erteilung einer Zulassung fĆ¼r das Humanarzneimittel "Uzpruvo - Ustekinumab" gemĆ¤Ć der Verordnung (EG) Nr. 726/2004 des EuropƤischen Parlaments und des Rates, URL: https://lnkd.in/dxqUhuA5, (Stand19.07.2024).
2 StelaraĀ® Fachinformation, Mai 2023
3 https://lnkd.in/dwGRh3BC
4 https://lnkd.in/dJKZsr9e
5 https://lnkd.in/djNgiahC
6 IQVIA PharmascopeĀ® and DKM Hospital, May 2024